ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1696

Prevalence and Incidence of Systemic Lupus Erythematosus in a Population-Based Registry of American Indian and Alaska Native People in the United States, 2007-2009

Elizabeth D. Ferucci1, Janet Johnston2, Jasmine Gaddy3, Lisa Sumner4, James Posever4, Tammy L. Choromanski1, Caroline Gordon5, S. Sam Lim6 and Charles G. Helmick7, 1Division of Community Health Services, Alaska Native Tribal Health Consortium, Anchorage, AK, 2Institute for Circumpolar Health Studies, Univeristy of Alaska Anchorage, Anchorage, AK, 3Medicine/Rheumatology, Oklahoma City Area Indian Health Service, Oklahoma City, OK, 4Medicine/Rheumatology, Phoenix Indian Medical Center, Phoenix, AZ, 5Rheumatology Research Group (East Wing), School of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom, 6Emory University School of Medicine, Division of Rheumatology, Atlanta, GA, 7National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: health disparities and systemic lupus erythematosus (SLE), Native Americans

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Epidemiology and Health Services Research II: Epidemiology in Systemic Lupus Erythematosus and Rheumatoid Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose:   Estimates of the prevalence and incidence of systemic lupus erythematosus (SLE) have varied widely but have consistently been high in women and minority populations.  The goal of this registry was to determine the prevalence and incidence of SLE in the US American Indian/Alaska Native (AI/AN) population. 

Methods:  This population-based registry was developed as a public health surveillance project within the Indian Health Service (IHS), in partnership with the Centers for Disease Control and Prevention (CDC).  The denominator was individuals: 1) included in the IHS active clinical population in 2007, 2008, and/or 2009 (2 or more visits to an IHS clinic in the past 3 years, at least one of which must be to a core medical clinic); and 2) residing in a community in one of 3 specified regions (Alaska, Phoenix, and Oklahoma City IHS Areas).  Potential SLE cases were identified based on International Classification of Diseases, Ninth Revision (ICD-9) codes for SLE or related connective tissue diseases in the IHS National Data Warehouse, a central repository for clinical and administrative data.  Detailed medical record abstraction was performed for each potential case.  Cases were defined as individuals with documentation of 4 or more of the ACR classification criteria for SLE.  Prevalence and 95% confidence intervals (CI) were calculated for 2007 overall and by region, sex, and age.   Age-adjusted rates were calculated using the standard projected 2000 US population.  Person-time incidence rates were calculated over the years 2007-2009 overall and by region, sex, and age. 

Results: Prevalence of SLE in 2007 and incidence from 2007-2009 are presented in the Table, including unadjusted and age-adjusted rates with 95% confidence intervals (CI).  Age-specific prevalence rates by sex are shown in the Figure.   The prevalence was highest in women, the age group 60-69, and the Phoenix Area of IHS.  The groups with the highest incidence were women, those in the age group of 40-49, and the Phoenix Area of the IHS.

Conclusion: The first population-based lupus registry in the US AI/AN population has demonstrated high prevalence and incidence of SLE in the IHS active clinical population, especially in women.  Our estimates are consistent with higher rates in minority populations, and are on the higher bound of previous estimates in the AI/AN population.

 

Table: Prevalence (2007) and Incidence (2007-2009) of SLE in the IHS lupus registry

 

Prevalence ( per 100,000 people)

Incidence (per 100,000 person-years)

 

Unadjusted (95% CI)

Age-adjusted (95% CI)

Unadjusted (95% CI)

Age-adjusted (95% CI)

Overall

134.5 (119.8-151.0)

177.7 (157.1-200.2)

5.9 (4.2-8.0)

7.4 (5.1-10.4)

Sex-specific

 

 

 

 

   Female

215.4 (190.3-243.7)

270.6 (237.5-307.0)

8.4 (5.8-11.8)

10.4 (6.6-14.6)

   Male

35.7 (25.5-49.8)

53.8 (36.2-77.1)

2.7 (1.3-5.2)

ND

Region-specific

 

 

 

 

   Alaska

110.2 (92.8-130.8)

148.7 (123.8-177.3)

4.8 (2.9-7.5)

6.1 (3.4-10.2)

   Phoenix

177.8 (149.2-211.8)

247.5 (204.5-297.3)

8.1 (5.0-12.6)

10.7 (6.2-17.5)

  Oklahoma

126.9 (88.9-179.1)

138.2 (92.6-199.5)

4.3 (1.1-11.7)

ND

* ND: not determined due to small number of cases.

Figure: Age-specific prevalence of SLE (2007) in the IHS lupus registry


Disclosure:

E. D. Ferucci,
None;

J. Johnston,
None;

J. Gaddy,
None;

L. Sumner,
None;

J. Posever,
None;

T. L. Choromanski,
None;

C. Gordon,
None;

S. S. Lim,
None;

C. G. Helmick,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-and-incidence-of-systemic-lupus-erythematosus-in-a-population-based-registry-of-american-indian-and-alaska-native-people-in-the-united-states-2007-2009/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology